Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double-blind, placebo controlled trial.

@article{Ballard2011UseOA,
  title={Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double-blind, placebo controlled trial.},
  author={Hubert Otho Ballard and Lori Ann Shook and Philip Bernard and Michael I. Anstead and Robert Kuhn and Vicki Whitehead and Deb Grider and Timothy N Crawford and Don Hayes},
  journal={Pediatric pulmonology},
  year={2011},
  volume={46 2},
  pages={111-8}
}
OBJECTIVE Since preventive therapies for bronchopulmonary dysplasia (BPD) are limited we treated preterm infants with azithromycin to decrease the incidence of BPD. METHODS Infants less than 1,250 g birth weight were randomized to azithromycin or placebo within 12 hr of beginning mechanical ventilation and within 72 hr of birth. The treatment group received azithromycin 10 mg/kg/day for 7 days followed by 5 mg/kg/day for a maximum of 6 weeks. Aspirates were collected during the study to assay… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 37 references

Similar Papers

Loading similar papers…